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This overview was evaluated by the development of diabetic retinopathy (DR) 
and the stem cell therapy approach. DR is a microvascular complication of diabetes 
mellitus, characterized by damage to the retinal blood vessels leading to progres-
sive loss of vision. However, the pathophysiological mechanisms are complicated 
and not completely understood yet. The current treatment strategies have included 
medical, laser, intravitreal, and surgical approaches. It is known that the use of 
mesenchymal stem cells (MSC), which has a great potential, is promising for the 
treatment of many degenerative disorders, including the eye. In retinal degen-
erative diseases, MSCs were ameliorated retinal neurons and retinal pigmented 
epithelial cells in both in vitro and in vivo studies. Stem cell therapies show promise 
in neurodegenerative diseases. However, it is very important to know which type 
of stem cell will be used in which situations, the amount of stem cells to be applied, 
the method of application, and its physiological/neurophysiological effects. 
Therefore, it is of great importance to evaluate this subject physiologically. After 
stem cell application, its safety and efficacy should be followed for a long time. In 
the near future, widespread application of regenerative stem cell therapy may be a 
standard treatment in DR.
Keywords: diabetic retinopathy, mesenchymal stem cells, cell therapy, regenerative 
stem cell therapy, neurodegenerative diseases
1. Introduction
The eye is an excellent structure, both an optical and a neuronal device. There 
are many diseases related to the eye. Each anatomical part of this organ may show 
a defect and cause an eye defect. Diabetic retinopathy is one of the most common 
complications of type I and type II diabetes. One of the main causes of blindness 
worldwide is diabetic retinopathy. Although glucose controls are helpful for other 
diabetic complications, they cannot prevent the development of retinopathy. 
While many studies have been done on the physiology of the retina, there are many 
unknown dark spots. Studies suggest that radicals derived from reactive oxygen play 
an important role in the development of diabetic retinopathy. Due to high oxygen 
consumption, the brain and retina are very sensitive to oxidative stress. Oxidative 
stress has been found to cause brain and retinal damage in both diabetic humans 
and experimentally diabetic rats. Although various hypoglycemic drugs have been 
developed for the treatment of diabetes mellitus (DM), complications associated 
with diabetes remain major medical problems. Therefore, the development of new 
treatments is of great interest. The mechanisms in the development and progression 
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of diabetic retinopathy are not yet fully understood as they are multifactorial and 
complex. Stem cell therapies for retinal diseases have been around for a long time. 
Few clinical trials are currently showing improvement [1].
The eye is the site of many acute or chronic physiopathological disorders, 
reversible or not, that can lead to partial or total vision loss or major changes in the 
quality of patients’ life. The search for innovative therapeutic strategies to correct 
these disorders is an important current issue. Gene and cell therapies are powerful 
therapeutic tools, but controlling the properties and spread of the injected material 
is a parameter that limits its application in humans. Anatomical isolation of the eye 
and ease of access, on the other hand, enable the use of such treatments, which have 
been previously developed in tissues and whose clinical application is complex [2].
Hillard Lazarus used mesenchymal stem cell (MSC) for the first time in 1995. 
Today, there are more than 400 applications in a wide variety of clinical fields 
such as inflammatory pathologies or immunological, fibrotic, or neurological 
disorders [3].
The use of MSC, which has a great potential, is promising for the treatment of 
many degenerative disorders, including the eye. In retinal degenerative diseases, 
MSC ameliorated retinal neurons and retinal pigmented epithelial cells in both 
in vitro and in vivo studies [1]. Diabetes is among the largest medical emergencies 
in the world. Hyperglycemia is responsible for a wide number of complications, 
with the vascular ones representing the leading cause of mortality. Stem cells have 
the unique ability to originate any organ or tissue and are capable of self-renewal. 
Among stem cells, great clinical interest is reserved for MSC [4].
2. Diabetes and diabetic retinopathy
The development of modern life has brought with it an inactive life [5]. The 
human population is constantly increasing, and diseases are also increasing. In 
addition, the expectation of prolonging life, lifestyle, and dietary habits that sup-
port obesity creates possible conditions for the development of diabetes. Diabetes 
is shown as the third cause of death in industrialized countries after cardiovascular 
diseases and cancer. It is stated that about 110 million people on a global scale 
suffer from diabetes mellitus. This type of diabetes is also called diabetes mellitus. 
The main symptom of this disease is the presence of sugar in the urine. A diabetic 
patient occurs every 8 minutes according to the research of a health institution. 
DM is the inability of sugar to enter the cell and perform its function as a result of 
the insufficiency of pancreatic insulin secretion or the ineffectiveness of insulin or 
the inability of insulin to function due to structural defects in the insulin molecule. 
Insulin produced in the pancreas is responsible for the transition of blood glucose 
into cells. When insulin is deficient, the level of glucose in the blood increases and it 
increases the permeability of the vessel by causing defects in the inner surface and 
outer wall of the vessel in the vascular tissue. Diabetes damages the retina the most 
in the eye tissue. It is predicted that diabetes mellitus will rise sharply in the next 
decade. Patients with diabetes suffer from life-limiting and threatening complica-
tions and suffer from diseases such as stroke, peripheral arterial diseases, and 
retinopathy. [6]. Diabetic retinopathy is the most common microvascular complica-
tion of DM, resulting in blindness worldwide. Diabetic retinopathy (DR) is a global 
problem, affecting approximately 100 million people worldwide. Blindness is 25 
times more common in diabetic patients than in non-diabetic patients. DR is the 
most common cause of blindness in patients aged 20–64 years in developed coun-
tries. The prevalence of the disease is related to the age of the cases and the duration 
of the disease. Biochemical changes detected in diabetic retinopathy increased 
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oxidative stress, nonenzymatic glycosylation, protein kinase-C activation, polyol 
pathway, and increased nitric oxide [7].
Retinal neurons provide normal visual function. Vision loss in diabetes should 
be explained as a disorder in the function of neurons. To date, most research has 
generally focused on retinal vascular changes rather than the effect of diabetes on 
the neural retina. As a result of many studies, it has been determined that changes 
in neuronal function and vitality are effective in the pathological mechanism of 
diabetic retinopathy that starts in the early stage of diabetes. Neurophysiological 
changes have been observed immediately after the onset of diabetes in both humans 
and experimental animals [8].
The most common cause of retinopathy is diabetes. Retinopathy is responsible 
for about a third of vision loss and blindness in children. Microaneurysms, non-
perfusion capillaries, hemorrhages and/or lipoprotein exudates, which are the 
onset of DR, indicate that DR is primarily a microvascular disease [9]. There is 
ample evidence of early retinal neurodegenerations in diabetes. Neuronal degener-
ations and early retinal disorders were observed in some animal models and studies 
in humans before the onset of diabetic vasculopathy [10]. Neurodegeneration, 
which causes thinning of the retina layer in animal studies, is not only limited to 
cell death and tissue loss but also causes functional disorders in neurotransmitters 
[11]. The most prominent feature of neurodegenerative diseases is increased neu-
ronal loss with apoptosis. Increasing neuron frequency is accepted as an important 
component of pathology in diabetic retinopathy. Early studies characterized 
vascular lesions in postmortem specimens of human retinas [12–14].
Indeed, neurophysiological changes have been observed immediately after the 
onset of diabetes in both humans and experimental animals. It has been reported 
that vascular changes such as permeability changes during diabetes occur 8 days 
after the onset of diabetes in rats. Capillary dilation and increased blood flow 
are the earliest signs of diabetes in both humans and animals. Capillaries begin 
to close within a few years in dogs whereas in about 1 year of diabetes in rats. 
Typical retinopathy begins to develop in humans at 5–10 years, with microaneu-
rysm, hemorrhage, macular edema, and neovascularization. The neural retina 
is transparent and invisible, so it is not visible on clinical examination. Vascular 
changes provide information about the course of the disease and the possibility of 
blindness. Apart from insulin therapy, the only proven treatment is laser photo-
coagulation, which destroys retinal regions with overt vascular disorders. This 
manipulation reduces macular edema and can improve visual acuity, but it cannot 
restore normal vision and prevent neuronal loss. If neurodegeneration begins 
shortly after the onset of diabetes, irreversible neuron damage occurs during laser 
therapy. Early neurophysiological and neurodegenerative changes should be con-
sidered as targets for current DR treatments. Psychophysical measurements also 
showed changes in vision in the early stage of diabetes onset. Contrast sensitivity 
decreases especially at mid and low spatial frequencies [1, 15].
Obesity is a major health problem in the world that is responsible for type II 
diabetes mellitus (DM) and its serious complications, such as retinopathy, cardio-
vascular disease, and nephropathy. In diabetic eyes, neovascularization results in 
blindness through a vitreous hemorrhage, retinal detachment, or glaucoma. Retinal 
hypoxia is the crucial factor for these complications [16]. Diabetic retinopathy is one 
of the most common complications of type I and type II diabetes. One of the main 
causes of blindness worldwide is diabetic retinopathy. Although glucose controls are 
helpful for other diabetic complications, they cannot prevent the development of 
retinopathy. The pathology of retinopathy is due to the deterioration of the vessels 
of the eye, which occurs due to various metabolic disorders in diabetic patients. 
These metabolic disturbances range from the level of vascular endothelial growth 
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factor (VEGF) to the accumulation of end products of its glycosylation. The primar-
ily tissue-damaging effects of chronic hyperglycemia cause a complex interplay of 
multiple mechanisms, which cause abnormal permeability within the retinal ves-
sels, and occlusion with ischemia and subsequent neovascularization. Current treat-
ments include laser photocoagulation and vitreotomy, but these treatments are not 
curative and do not target the pathological mechanism of the disease. Various stud-
ies have been conducted in diabetic rats and human models. Immunohistochemical 
studies were able to show that intravitreally injected stem cells were localized to 
the inner retina and it has been stated that this increases visual function. Human 
clinical trials are ongoing to evaluate the safety, success, and utility of hematopoi-
etic stem cell (HSC) injection in treating retinal vascular diseases. Two patients 
with diabetic retinopathy injected with HCC showed improvement in visual acuity 
and ophthalmic measurements even 12 weeks after treatment. The mechanism of 
the behavior of HSC is unclear, but is thought to be dependent on paracrine signal-
ing. In animal models, intravitreal HSC has been shown to improve retinal damage 
caused by light, ischemia, and diabetes. Apart from HSC, other stem cells such as 
mesenchymal stem cell (MSC), endothelial progenitor cell (EPC), and adipose 
stromal cell are also being investigated for their use in the treatment of diabetic 
retinopathy. Diabetes mellitus causes both functional and structural deficiencies 
by affecting both the peripheral and central nervous systems. Peripheral disorders 
develop within a few weeks after the onset of diabetes, while central disorders take 
months to develop [17]. Diabetic retinopathy is a major complication of diabetes. 
However, the effect of a prediabetic condition on the retina has not been clarified. 
Prediabetes refers to a metabolic disorder defined by glycemic variables lower than 
diabetes but higher than normoglycemia and considered a high-risk condition for 
the development of diabetes. It has been stated that the majority of prediabetic 
patients will eventually develop diabetes [18, 19]. Current treatments for DR as 
laser photocoagulation, intravitreal anti-VEGF agents, intravitreal corticosteroids, 
and vitreoretinal surgery are applicable only at advanced stages of the DR and are 
associated with significant adverse effects [20]. Therefore, new treatments for the 
early stages of the DR are needed. Retinal diseases are the leading cause of vision 
loss in the world. Because of the ability of stem cells to self-renewal and differentia-
tion to various types of cells, stem cells are becoming an attractive source of cell 
therapy in repairing damaged cells as retina pigment epithelium or photoreceptors. 
Consequently, retinal stem cell therapy is one of the promising therapeutic alterna-
tives to recover vision [21].
3. Stem cells
The organism begins to form from a cell and then develops into a complete 
organism with more than 200 cell types. This phylogenetic trend, the tendency to 
switch from pluripotent cells to mature cells is an integral part of human develop-
ment. This process, in which cells differentiate and turn into cells without plasticity, 
is necessary to form all special tissues of the human and to minimize the risk of 
tumor proliferation. Basically, for a cell to be accepted as a stem cell, this cell should 
first be able to renew itself without losing its plasticity, and then lose its plasticity 
and differentiate into different sub-cell types [22]. A stem cell is an undifferenti-
ated cell with the capacity to self-renewal and differentiate. These cells have also 
the capacity to differentiate into special cells that make up tissues and organs. 
Self-renewal is the capacity for a cell to reproduce indefinitely by maintaining its 
undifferentiated state. Differentiation potential is the capacity for a cell to differen-
tiate into one or more types of mature cells.
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In addition, stem cells are also characterized by maintaining a certain calm-
stagnant state, apart from their capacity for self-renewal and differentiation. This 
quiescent phase is the G0 phase of the cell cycle, in which cells enter in the absence 
of mitotic factors. With this calm phase, stem cells can protect themselves against 
possible “attacks” and maintain their vitality. However, none of these features 
are sufficient to define the ‘root’ character of the cell. In fact, it should have the 
potential to rebuild the tissue’s excellent function in the long run. This means a large 
number of cellular divisions and differentiation in vivo. These properties also play a 
vital role in organogenesis and adult tissue regeneration. There are many stem cells 
used and studied in research. Particularly, some researchers can find new stem cell 
sources today [23–25].
The two largest types of stem cells in mammals are embryonic stem cells isolated 
from the inner cell mass of the blastocyst and adult stem cells found in most adult 
tissues.
3.1 Embryonic stem cells (ESC)
They are the first discovered and studied stem cells. They are cells that can 
renew themselves and have the capacity to differentiate into all cell types that can 
form a whole organism.
3.2 Adult stem cells
With the development of the embryo, embryonic pluripotent stem cells are 
replaced by stem cells with a more limited capacity, which will provide organ and 
tissue formation. Cells of different tissues are now specialized. Organs need a 
mechanism to regenerate cells by replacing cells lost by apoptosis or lesion, thus 
maintaining their homeostasis. An adult loses about 20 billion cells in a day. This 
requires a permanent restructuring system [26]. Some organs such as the brain, 
heart, and kidney are less regenerated [27]. On the other hand, tissues such as bone 
marrow, skin, and intestines are constantly renewed. To ensure the regeneration 
prosess, organs have a cell reservoir; adult stem cells which serve throughout life. 
Their stocks are provided by the balance between self-renewal and differentiation 
capacities. Adult stem cells are also known as somatic stem cells. It is assumed that 
all organs of the body have mature stem cells, and in most organs, they are active 
throughout life. They constantly form new cells to ensure tissue regeneration (skin, 
cornea, bone marrow, intestine) [28–30]. In some organs, these cells become active 
after birth and then go into dormancy. We see them in organs with slow or almost 
no cellular regeneration; it is seen only in organs such as the brain and liver, where 
stem cells divide only during serious injuries or rarely [31, 32]. Hematopoietic stem 
cells, stromal stem cells, and stem cells in organs are adult stem cells.
Bone marrow contains two types of cells: hematopoietic stem cells (HSC) and 
stromal mesenchymal stem cells (MSC). HSC can form all mature hematopoietic 
cells such as myeloid and lymphoid. MSC plays a supportive role in hematopoiesis. 
Bone marrow also contains other types of cells. Progenitor endothelial cells (PEC) 
are found in the marrow as well as adult multipotent progenitor cells [33]. When 
necessary, PEH enters the circulation and plays a role in angiogenesis. In addition, 
some studies refer to bone marrow stem cells (F-MSCs), which represent a hetero-
geneous stem cell population. These cells can differentiate into many different types 
of cells, such as hepatocytes, endothelial cells, epithelial cells, cardiac or skeletal 
muscle cells, neuronal cells, or astrocytes. This indicates that bone marrow cells 
have the potential to differentiate into cells of another tissue [34]. Stem cells are 
ubiquitous. Some niches are yet to be discovered. Although bone marrow-derived 
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stem cells have been cited as a potential resource for regenerative therapy, their 
potential and usefulness are still open to debate [35, 36].
Deterioration in tissues or organ functions for any reason constitutes a very 
important problem in terms of seriously affecting an individual’s quality of life. 
For this reason, regenerative medicine is concerned with repairing the damage and 
restoring normal body functions through stem cell therapies. Advances in stem 
cell research have shown cell-based therapy as a useful option to treat medically 
incurable diseases [36]. Stem cells can migrate to damaged tissue. The effect and 
cellular mechanisms of stem cells vary according to their environment. They have 
excellent plasticity that allows these cells to adapt to their environment and act 
appropriately [33].
“Plasticity” is the ability of a stem cell to acquire different differentiation 
programs under certain microenvironmental conditions. Endogenous MSC or 
exogenously administered MSC can migrate to the injured tissue and participate in 
its healing. The therapeutic effects of MSC can be attributed to its ability to secrete 
a wide variety of paracrine factors. These mechanisms are likely independent, 
but they can also act together. In many cases, a combination of these protective 
mechanisms can work together to heal the damage [37]. However, the mechanism 
of the therapeutic effect of stem cell is still open to debate. There are two basic 
explanations; these are cell differentiation and the paracrine effect of stem cells. 
The combination of these two mechanisms seems to be a third theory [38].
4. Mesenchymal stem cells and retinal degenerations
Retinal degenerations are pathologies that affect the light-sensitive cells of the 
retina, photoreceptors, cones, and rods. Cell therapy is accepted as an interesting 
alternative for retinal degenerations. A mouse model of retinal degeneration has 
been shown to improve visual function after transplantation of photoreceptors [39]. 
Other cells, including MSC, also show great potential by altering photoreceptors or 
protecting against degenerations due to their paracrine effects [40]. Some research-
ers also emphasize that MSC can differentiate into retinal cells, especially photo-
receptor-like cells. This plasticity feature of MSC has been observed in vitro [41]. 
It has also been observed in vivo by subretinal injection in a rat model with retinal 
degeneration [42]. These results reveal the possibility of regenerative therapy in 
pathologies involving photoreceptor losses.
In general, cellular therapy works in two ways: to replace dead cells in the tissue 
to restore tissue function or to prevent/attenuate/slow tissue degeneration by reduc-
ing inflammatory infiltration or reduce apoptosis and cell death phenomena.
5. Stem cell and eye
The eye is a small organ, and the number of stem cells required therapeutically 
is theoretically less than in larger organs. Compared to other internal organs, the 
retinal environment is easily accessible with small-gauge vitrectomy needles, greatly 
increasing the potential for stem cell-based therapy for the treatment of retinal 
degenerative diseases. The retina is layered and thin. It depends on the preservation 
of cells, nerve anatomy, and synaptic networks to maintain vision. Retinal neuron 
connectivity is an important therapeutic goal to alleviate blindness in millions of 
people worldwide for the preservation or restoration of the original neural structure 
of the retina and photoreceptor [43]. The emergence of studies shows the possibility 
of cell regeneration in the adult central nervous system, which makes it possible 
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to envision the implantation of stem cells or progenitor cells as an approach to cell 
therapy. The restorative approach offers strong hope, given that key questions about 
the biology of development need to be explored. The transplantation of differenti-
ated or undifferentiated retinal tissue (embryonic, newborn) in the subretinal 
position of the graft poses the problem of its structural and functional organization.
It is seen that different types of stem cells are used considering transplantation 
studies. When we look at transplantation studies, in studies using different types 
of stem cells (retina progenitor cell, neural stem cell, bone marrow-derived stem 
cell, and embryonic stem cell), although they settle in the retina, they are not able 
to express retinal-specific markers and cannot establish synaptic connections are 
encountered [44].
The discovery of stem cells has caused great excitement in the hopes of using 
such treatments to restore vision. Already, stem cells in the anterior segment of the 
eye have a remarkable clinical effect. Stem cell therapy provides re-epithelialization 
of the cornea and improves vision. The trabecular meshwork, located on the inner 
side of the junction of the sclera and the cornea, can also be regenerated with stem 
cells [38]. However, the most interesting studies have been done in the posterior 
segment of the eye. Most retinal degenerations begin with the loss of a neuron or 
damage to a neuron. Therefore, these cells should be replaced with a cell layer that 
is differentiated and functional in the appropriate medium. Sometimes pathology 
develops and destroys many cells. In this case, a graft consisting of several layers is 
required. To perform a transplant treatment for blindness, progenitor neuronal cells 
are isolated and transferred to different cells of the retina.
Studies on neuronal cell cultures that can differentiate are done. Today, very few 
of these differentiation mechanisms have been fully elucidated. Therefore, the use 
of cell transplantation in the retina seems distant [45].
Considering that stem cell therapy is promising in retinal diseases, studies 
were started with embryonic stem cells, and induced pluripotent stem cells were 
obtained. Many retinal cells such as retinal pigment epithelium, photoreceptors, 
and ganglion cells were obtained from induced pluripotent stem cells [46].
It is stated that the neuroretina, which is attached to the pigment epithelium 
(RPE), has a complex structure. Therefore, it has been stated that there are three 
different cells that can be considered in cell therapy: neuroretina (photorecep-
tors, bipolar cells, ganglion cells, and glial cells), RPEs, and vascular endothelial 
cells. Depending on retinal diseases, strategies to place different cells need to be 
developed [47].
6. Conclusion
Diabetic retinopathy (DR) is one of the largest causes of vision loss worldwide. 
The use of autologous stem cells for organ reconstruction offers a potential solution 
for the replacement of tissue or whole organs mechanisms in the development and 
progression of DR are not fully understood yet. Although many studies have been 
done about retinal physiology, many unknown dark spots are available about it. Stem 
cell therapy appears to be a possible option both to prevent neurovascular damage 
and to repair the damaged retina. Mesenchymal stem cell attracts great attention in 
retinal degenerations due to their ability to differentiate into neurons. However, the 
way and amount of stem cell administration will create different effects, it is impor-
tant to know the effect of cell therapy on body after administration in relation to its 
use in the clinical practice.
To date, no treatment has been developed for the regeneration of retinal  
vasculature damage resulting from prolonged hyperglycemia. Cell therapy seems 
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to be a possible option both to prevent neurovascular damage and to repair dam-
aged retina [48]. Although clinical evaluations and retinal autopsies of diabetic 
patients provide information about the progression and features of diabetic 
retinopathy, its pathophysiological mechanism is not yet understood. Studies on 
animal models continue in order to better understand the development of diabetic 
retinopathy at the molecular and cellular level [49]. Retina, in the nervous system, 
provides a suitable environment to study the functions and distribution of stem 
cells. It is stated that intravenously administered mesenchymal stem cell transplan-
tation can inhibit retinal apoptotic cells, reduce inflammatory responses, and limit 
the spread of damage [50].
In a study in which intravitreal mesenchymal stem cell application was 
performed, some physiological parameters were examined and it was seen that 
although there were decreases in body weight in diabetics, there was no change in 
body weight in the group administered intravitreal stem cells. These findings were 
interesting for us. While it was reported that body weight increased significantly 
in the mouse model in which the human adipose tissue-derived mesenchymal stem 
cell was transplanted via the tail. It has been stated that intravitreal stem cell appli-
cation also reduces intraocular pressure and provides a better cognitive function in 
the diabetic model [51].
As a result, more clinical trials should evaluate the application methods, the 
timing of the practice, using cell count and repetition dose of stem cell and their 
results. In the near future, the regenerative stem cell therapy may be a standard 
treatment in many degenerative eye disorders.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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